ligufalimab (AK117)

News alerts, weekly reports and conference planners

Company:

Akesobio

Drug class:

CD47 inhibitor

Related drugs:

‹

›

HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3

Associations
(2)